Clinical Trials in China / NCT07811895
Starting soon
Not applicable
Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer
NCT07811895 · tracked via the Priya Life Science China tracker
Condition(s) studied
TirzepatideFrozen Embryo TransferObesity
Investigational drug(s) / intervention(s)
Dual GIP/GLP-1 receptor agonist: 16 weeks treatment
Study summary
To evaluate the efficacy and safety of Dual GIP/GLP-1 receptor agonist pretreatment on reproductive outcomes in obese women before frozen embryo transfer.
Eligibility
Inclusion Criteria:
1. Women aged 20-40 years;
2. Body Mass Index(BMI) ≥ 28kg/m2;
3. Women who intend to undergo frozen-thawed embryo transfer;
4. At least one embryo available for transfer;
5. Be capable of giving informed consent.
Exclusion Criteria:
1. Women who have been diagnosed with diseases affecting uterine cavity or endometrial receptivity;
2. Presence of endocrine disorders that may significantly affect body weight;
3. Use of drugs that may cause significant weight changes within 8 weeks before screening;
4. Presence of contraindications to the use of dual GIP/GLP-1 receptor agonist;
5. Previous bariatric surgery (e.g., gastric bypass) or planning to undergo such surgery during the study period;
6. Serum triglycerides (TG) \> 5.64mmol/L;
7. Calcitonin≥50 ng/L;
8. Presence of medical contraindications to assisted reproductive technology and/or pregnancy;
9. Any other condition considered inappropriate for participation by the investigator.
Primary outcome measure(s)
- Good birth outcome rate — at delivery
good birth outcome is defined as live birth(s) at ≥37 weeks, with infant birth weight between 2500 and 4000g and without a major congenital anomaly.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| RenJi Hospital | Shanghai | Shanghai Municipality |
More RenJi Hospital trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07811895 on ClinicalTrials.gov ↗ ← All trials in China